Company Overview and News
During the Farnborough International Airshow, Boeing has shared its current market outlook. In total, Boeing has valued the commercial aircraft and services market at $15 trillion. There are a lot of ways to slice and dice the numbers but what we are really interested in, in this article series, is to find out how much of the commercial aircraft market is still open to jet makers including but not limited to Boeing (BA) and Airbus (OTCPK:EADSF).
BOE BDRAF BA
As the joint venture between Airbus (OTCPK:EADSF/OTCPK:EADSY) and Bombardier (OTCQX:BDRAF) on the C Series came into effect, Airbus has renamed the C Series family to fits its own product portfolio. The aircraft itself has not changed, but it is now complementing the Airbus single aisle line up. In this report, we briefly look at the benefits and the backlog.
The Farnborough biennial air show alternating with the Paris Airshow. This year the Fanborough Airshow will be hosted from the 16th of July until the 22nd of July. The air show is typically used by jet makers and airlines to announce new orders and products.
AFRAF GEC GE BOE GNE BDRAF BA AFLYY
JGH is a closed-end fund sponsored by Nuveen, seeking high current income from below investment grade securities throughout the world.
"NHF" BDRAF HCT.RT LLOBF JGH MS LLOY BDRBF LYG LLPH LLPK LLPJ S LLPE LLPD LLPG NHF LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET